

Lori Friedman, PhD

Senior Director, Translational Oncology, Genentech, Inc.

Lori Friedman was trained in Molecular and Cell Biology, earning her PhD from the University of California, Berkeley in 1995, and completing postdoctoral research at Cambridge University, UK in 1998. Lori joined the biotech company Exelixis, Inc. as a research scientist, where she led multiple oncology research projects and advanced to become the Director of the Signal Transduction Research department. In 2004 Lori joined Genentech where she continued to focus on targeting key cancer pathways. She was attracted to Genentech because of the palpable commitment to helping patients by drawing on scientific insights. She is Senior Director of the Translational Oncology department, whose research includes validation of new oncology targets, understanding mechanism of action and mechanism of resistance of compounds, in vitro and in vivo pharmacology, and using preclinical cancer models to predict which patients will benefit from new therapeutic agents. In addition to her research, Lori has served as a Council Member of the AACR Women in Cancer Research (WICR), is a core team member of Genentech Women in Science and Engineering (gWISE), was honored with the Healthcare Business Women "Rising Star Award" in 2014, serves as a Board member for Project Scientist, mentors scientists, and is a Scientific Editor of Cancer Discovery journal. Lori has published 87 peer-reviewed scientific manuscripts and is an inventor on 24 issued patents.